Cargando…
Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge
Kirkham and colleagues presented an original study about cancer survivors in Canadian population and reported that the odds of several cardiovascular disease risk factors are higher among middle-aged. Several risk factors are connected to a toxic lifestyle and are associated with cardiovascular dise...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985765/ http://dx.doi.org/10.3390/curroncol28010030 |
_version_ | 1783668317476618240 |
---|---|
author | Loreti, Claudia Castelli, Letizia Coraci, Daniele Fusco, Augusto Giovannini, Silvia Padua, Luca |
author_facet | Loreti, Claudia Castelli, Letizia Coraci, Daniele Fusco, Augusto Giovannini, Silvia Padua, Luca |
author_sort | Loreti, Claudia |
collection | PubMed |
description | Kirkham and colleagues presented an original study about cancer survivors in Canadian population and reported that the odds of several cardiovascular disease risk factors are higher among middle-aged. Several risk factors are connected to a toxic lifestyle and are associated with cardiovascular diseases and general health status. The paper is very relevant in managing oncological patients. A particular attention should be given to some anamnestic data about the presence of other pathologies (as self-reported diabetes and hypertension) and drug therapy with particular consideration of angiotensin-converting enzyme inhibitors that present a protective action against cardiovascular events and reduce the incidence of type II diabetes. In order to identify and intervene on risk factors, clinicians should depict the pharmacological therapy taken by the study population, assuming that in the elderly this may be potentially protective on cardiovascular risk profile compared to younger cancer survivors. |
format | Online Article Text |
id | pubmed-7985765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79857652021-03-24 Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge Loreti, Claudia Castelli, Letizia Coraci, Daniele Fusco, Augusto Giovannini, Silvia Padua, Luca Curr Oncol Comment Kirkham and colleagues presented an original study about cancer survivors in Canadian population and reported that the odds of several cardiovascular disease risk factors are higher among middle-aged. Several risk factors are connected to a toxic lifestyle and are associated with cardiovascular diseases and general health status. The paper is very relevant in managing oncological patients. A particular attention should be given to some anamnestic data about the presence of other pathologies (as self-reported diabetes and hypertension) and drug therapy with particular consideration of angiotensin-converting enzyme inhibitors that present a protective action against cardiovascular events and reduce the incidence of type II diabetes. In order to identify and intervene on risk factors, clinicians should depict the pharmacological therapy taken by the study population, assuming that in the elderly this may be potentially protective on cardiovascular risk profile compared to younger cancer survivors. MDPI 2021-01-04 /pmc/articles/PMC7985765/ http://dx.doi.org/10.3390/curroncol28010030 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Comment Loreti, Claudia Castelli, Letizia Coraci, Daniele Fusco, Augusto Giovannini, Silvia Padua, Luca Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge |
title | Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge |
title_full | Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge |
title_fullStr | Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge |
title_full_unstemmed | Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge |
title_short | Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge |
title_sort | polipharmacy and multimorbity in oncological patients: an open challenge |
topic | Comment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985765/ http://dx.doi.org/10.3390/curroncol28010030 |
work_keys_str_mv | AT loreticlaudia polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge AT castelliletizia polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge AT coracidaniele polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge AT fuscoaugusto polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge AT giovanninisilvia polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge AT padualuca polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge |